Glucarpidase should soon be approved throughout Europe to treat methotrexate toxicity. The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently recommended the ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.

A new model can predict which patients are more likely to experience side effects from long-term methotrexate (MTX) use, research suggests. Patients with a lower risk profile may benefit from less ...

Methotrexate is a cornerstone in oncology and immunosuppression, but its propensity to disrupt spermatogenesis, deplete antioxidants and trigger apoptosis within the testicular microenvironment ...

A major new study has found a method to identify people who may experience blood, kidney, or liver related side effects from methotrexate, the most commonly used immune-suppressing medicine with 1.3 ...

A prospective trial of prophylaxis and treatment (P+T) of acute tumor lysis syndrome (ATLS) with rasburicase (R) and nonalkaline hydration in children and adolescents (C+A) with intermediate- (Group B ...

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by investigators ...

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study. Using data from ...

Please provide your email address to receive an email when new articles are posted on . Patients who received glucarpidase for acute kidney injury from methotrexate treatment had improved kidney ...

Glucarpidase may improve kidney function and other sequelae in patients with methotrexate-induced acute kidney injury. High-dose methotrexate frequently causes acute kidney injury (MTX-AKI), ...